Abstract
The major drug-metabolizing human hepatic cytochrome P-450s (CYPs; CYP1A2, 2C9, 2C19, 2D6, and 3A4) coexpressed functionally inEscherichia coli with human NADPH-P-450 reductase have been validated as surrogates to their counterparts in human liver microsomes (HLM) using automated technology. The dealkylation of ethoxyresorufin, dextromethorphan, and erythromycin were all shown to be specific reactions for CYP1A2, CYP2D6, and CYP3A4 that allowed direct comparison with kinetic data for HLM. For CYP2C9 and CYP2C19, the kinetics for the discrete oxidations of naproxen and diazepam were compared to data obtained using established, commercial CYP preparations. Turnover numbers of CYPs expressed in E. coli toward these substrates were generally equal to or even greater than those of the major commercial suppliers [CYP1A2 (ethoxyresorufin), E. coli 0.6 ± 0.2 min−1 versus B lymphoblasts 0.4 ± 0.1 min−1; CYP2C9 (naproxen), 6.7 ± 0.9 versus 4.9 min−1; CYP2C19 (diazepam), 3.7 ± 0.3 versus 0.2 ± 0.1 min−1; CYP2D6 (dextromethorphan), 4.7 ± 0.1 versus 4.4 ± 0.1 min−1; CYP3A4 (erythromycin), 3 ± 1.2 versus 1.6 min−1]. The apparentKm values for the specific reactions were also similar (Km ranges for expressed CYPs and HLM were: ethoxyresorufin 0.5–1.0 μM, dextromethorphan 1.3–5.9 μM, and erythromycin 18–57 μM), indicating little if any effect ofN-terminal modification on the E. coli-expressed CYPs. The data generated for all the probe substrates by HLM and recombinant CYPs also agreed well with literature values. In summary, E. coli-expressed CYPs appear faithful surrogates for the native (HLM) enzyme, and these data suggest that such recombinant enzymes may be suitable for predictive human metabolism studies.
Footnotes
-
Send reprint requests to: Dr. Robert Riley, Department of Physical & Metabolic Sciences, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire. LE11 5RH UK. E-mail:Rob.Riley{at}charnwood.gb.astra.com
-
We acknowledge support for this project from the Biotechnology & Biological Research Council, UK-Department of Trade and Industry, and the LINK consortium of pharmaceutical companies: Astra, Glaxo-Wellcome, Janssen Pharmaceutica, Lilly, Novo Nordisk, Parke-Davis, Pfizer, Roche Products, Sanofi-Winthrop, Servier, Smith-Kline Beecham, Wyeth-Ayerst, and Zeneca.
- Abbreviations used are::
- CYP
- cytochrome P-450
- TN
- turnover number
- HLM
- human liver microsome(s)
- Clint
- intrinsic clearance
- EROD
- ethoxyresorufinO-deethylation
- β-NADPH
- β-nicotinamide adenine dinucleotide phosphate, reduced form
- RSP
- robotic sample processor
- SPE
- solid phase extraction
- Received March 17, 1999.
- Accepted June 15, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|